Once again we see what seems to be logical isn’t necessarily the way it actually works! In a surprising study result, it was shown that the use of intermittent androgen-deprivation therapy (IADT) for prostate cancer is not associated with fewer long-term adverse events than continuous ADT! Who would have guessed? We all thought that intermittent [...]
Intermittent hormone therapy (IHT) as opposed to continuous hormone therapy (CHT) provides a better quality of life (QoL) for men with locally advanced prostate cancer. However, there is a debate created by a few major research protocols that have been inconclusive as to the difference in achieving the ultimate goal, survival despite prostate cancer. Researchers [...]
Researchers performed a randomized, placebo-controlled Phase II trial of men with localized prostate cancer and a rising prostate-specific antigen (PSA) level post-primary treatment. The men were randomized to receive Avodart (dutasteride @ 0.5 mg/day) or to receive a placebo. All of the men were receiving intermittent androgen deprivation therapy (IADT), which was stopped at month [...]
There has been much conversation surrounding the use of intermittent androgen deprivation (IAD) as opposed to continuous androgen deprivation (CAD) in men with prostate cancer who need hormone therapy (ADT). The question that has been at issue is if either method is superior to the other. There have been studies that have concluded that they [...]
Start A Cure Research Project of the Day A Simple and Novel Approach to Enhance the Efficacy of Intermittent Androgen Deprivation Therapy for Prostate Cancer Patients There comes a time when most of us will go on to Androgen Deprivation Therapy (ADT). Depending upon your philosophy, your doctors philosophy and your numbers (Gleason grade and [...]
The Journal of Clinical Oncology, published an article by Niraula et al. that searched the general literature published through August 2012. They searched MEDLINE, EMBASE, the Cochrane Library, as well as most major conference proceedings. Their criteria for inclusion included randomized, controlled trials of intermittent hormone therapy (IADT) as compared to continuous hormone therapy (CADT) [...]
On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy for men with advanced prostate cancer with bone metastasis is not [...]
On June the 4th I reported on the SWOG-9346 study presented at the ASCO Meeting in Chicago (http://advancedprostatecancer.net/?p=3264). In the presentation by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center, Dr. Hussain reported that intermittent androgen-deprivation (IAD) therapy is not as good as continuous hormone therapy with regard to [...]
At the American Society for Clinical Oncology's (ASCO) meeting there was an upsetting plenary presentation made on June 3. Data was presented by principal investigator, Maha Hussain, M.D., F.A.C.P., from the University of Michigan Comprehensive Cancer Center. Dr. Hussain discussed the findings from the phase III clinical trial SWOG-9346, the largest such study to date [...]
Changing the Standard of Care for Men with Recurrent and Advanced Prostate Cancer, Men receiving androgen deprivation therapy (ADT) for the treatment of advanced or metastatic prostate cancer know all to well the terrible side effects this treatment modality can cause. These side effects can include fatigue, hot flashes, mood swings, inability to concentrate as [...]
